Do tP53 mutations and MDM2 ( SNP309 ) identify subgroups of AML patients with impaired outcome?
Our results show that TP53mut analysis and MDM2(SNP309) genotyping may be useful tools for prognostication, risk stratification, and selection of patients most likely to benefit from new drugs targeting the p53 signaling pathway.
Epistasis between SNPs within the TSHB and ADAMTS16 genes may increase the risk of POF in Korean women.